What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
NNMT-inhibitor small molecule for metabolic research
Overview
Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide using S-adenosyl-methionine as the methyl donor. By inhibiting NNMT, the compound is studied for its reported effects on cellular nicotinamide and NAD+ salvage flux and on adipocyte energy expenditure, which places it in the metabolic and body-composition research literature alongside other metabolism-modulating compounds. It is a quaternary quinolinium small molecule, not a peptide. Vialdyne supplies Amino-1MQ as a research reagent released against an HPLC purity specification with mass-spec identity confirmation; the released-batch COA covers HPLC purity, identification, water content, residual solvents, heavy metals, and microbial limits against a small-molecule reagent specification. Because salt form and exact identity vary across the market under the 'Amino-1MQ' label, lot identity is documented on the COA, confirm the intended form at order placement.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for 5-Amino-1MQ, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →5-Amino-1MQ
VD260428-10AM016 · 99.59%
VerifiedRequest full COA →5-Amino-1MQ
VD260428-50AM017 · 99.28%
VerifiedRequest full COA →5-Amino-1MQ
VD260428-5AM015 · 99.25%
Regulatory note
Research-use-only small-molecule reagent (NNMT inhibitor); not an approved drug in any jurisdiction and not for human or veterinary use.
Selected literature
Frequently asked questions
It inhibits nicotinamide N-methyltransferase (NNMT). NNMT consumes nicotinamide and the universal methyl donor S-adenosyl-methionine (SAM) to produce 1-methylnicotinamide. Research interest centres on the hypothesis that inhibiting NNMT preserves nicotinamide for NAD+ salvage and shifts cellular methylation and energy-expenditure balance, which is why the compound appears in metabolic and adipose-tissue research. These are preclinical research findings; Vialdyne supplies the compound strictly as a research reagent and makes no therapeutic claim.
No, it is a small-molecule quaternary quinolinium compound, not a peptide, so the release follows a small-molecule reagent specification: HPLC purity, mass-spec identity, water, residual solvents, heavy metals, and microbial limits, rather than peptide-style sequence confirmation. Because salt form and exact identity vary across the market under the 'Amino-1MQ' label, the released-batch COA documents the lot identity; confirm the form you need at order placement.
Related peptides
